Ramakrishnan A S, Kothari Jagdish, Dabas Surender Kumar, Munnikrishnan Venkatesh, Sudheer O V, Vishnoi Jeewan Ram, Singh Shivendra, Dixit Jagannath, Nayak Sandeep, Sharma Ashwani, Parikh Devendra, Paneer Venkat, Kapoor Priya, Somashekhar S P, Bharadwaj Krishna M S, Gupta Divya, Dahiya Akhil
Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India.
GI and Hepatobiliary Services, HCG Cancer Centre, Ahmedabad, Gujarat, India.
J Robot Surg. 2025 May 16;19(1):222. doi: 10.1007/s11701-025-02375-5.
This multi-centric real-world study was carried out to assess the perioperative and histopathological clinical outcomes of rectal resections employing open, laparoscopic, and robotic-assisted techniques. A retrospective chart review was undertaken for patients who underwent rectal resections for Stages I, II, and III rectal cancer (RC) between April 2012 and August 2023. All surgical procedures were performed with the principles of total mesorectal excision (TME) or partial mesorectal excision (for tumors located higher in the rectum). The study analyzed data from 829 patients of which 314 were in the robotic-assisted group (RAS), 206 in the laparoscopic surgery group (LG), and 309 in the open-surgery group (OG). The TNM staging and location of RC were evenly distributed across the three groups. The RAS group had a significantly lower length of hospital stay than LG and OG. Compared to LG and OG, the RAS group had less blood loss and postoperative complications, but significantly longer mean operating room time. The conversion rate of the RAS group was significantly lower than that of the LG group (p = 0.03). In comparison to the OG and LG groups, the RAS group had significantly lower (p < 0.05) rates of positive circumferential resection margin (CRM). Adjuvant treatment was administered in the RAS group significantly earlier (median, 24.5 days, IQR 18-37) compared to the LG (median, 31 days, IQR 23-41) and OG (median, 32.5 days, IQR 27-42). This largest multi‑centric study by the ICRR group has validated the value of a relatively newer technology like RAS in real-world Indian settings for rectal resections.
这项多中心真实世界研究旨在评估采用开放、腹腔镜和机器人辅助技术进行直肠切除术的围手术期和组织病理学临床结果。对2012年4月至2023年8月期间接受I、II和III期直肠癌(RC)直肠切除术的患者进行了回顾性病历审查。所有手术均按照全直肠系膜切除(TME)或部分直肠系膜切除(适用于直肠高位肿瘤)的原则进行。该研究分析了829例患者的数据,其中314例在机器人辅助组(RAS),206例在腹腔镜手术组(LG),309例在开放手术组(OG)。RC的TNM分期和位置在三组中分布均匀。RAS组的住院时间明显短于LG组和OG组。与LG组和OG组相比,RAS组的失血量和术后并发症更少,但平均手术时间明显更长。RAS组的中转率明显低于LG组(p = 0.03)。与OG组和LG组相比,RAS组的环周切缘阳性(CRM)率明显更低(p < 0.05)。与LG组(中位数31天,IQR 23 - 41)和OG组(中位数32.5天,IQR 27 - 42)相比,RAS组的辅助治疗开始时间明显更早(中位数24.5天,IQR 18 - 37)。ICRR组的这项最大规模多中心研究证实了RAS等相对较新的技术在印度真实世界环境中进行直肠切除术的价值。